Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HFO vs HFA Propellant Induced Bronchospasm in Asthma
NCT05850494Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- May 2023
- Primary completion
- Aug 2023
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
A Phase 3 trial of HFO MDI in asthma, sponsored by AstraZeneca. Started May 2023; status: completed.
02
Drugs
HFO MDI
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05850494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05850494.